21
Participants
Start Date
August 19, 2019
Primary Completion Date
October 30, 2021
Study Completion Date
October 30, 2021
Lanadelumab
Participants will receive 150 mg dose of lanadelumab every 2 or 4 weeks, depending on the participants age, over the 52-week treatment period.
Semmelweis Egyetem., Budapest
Icahn School of Medicine at Mount Sinai, New York
Charité - Universitätsmedizin Berlin., Berlin
Institute Asthma and Allergy, Chevy Chase
Hospital Universitario La Paz. Paseo de la Castellana, Madrid
Clinical Research Center of Charlotte, Charlotte
Toledo Institute of Clinical Research Asthma & Allergy Center, Toledo
Bernstein Clinical Research Center, Cincinnati
Klinikum der Johann-Wolfgang Goethe-Universitat., Frankfurt
Washington University School of Medicine, St Louis
Hämophilie Zentrum Rhein Main GmbH, Mörfelden-Walldorf
AARA Research Center, Dallas
IMMUNOe Research Centers, Centennial
AIRE Medical of Los Angeles, Santa Monica
Allergy & Asthma Clinical Research, Walnut Creek
Hudson-Essex Allergy, Belleville
Yang Medicine, Ottawa
Lead Sponsor
Shire
INDUSTRY